CTOs on the Move

Visus Therapeutics

www.visustx.com

 
Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOL™), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.
  • Number of Employees: 25-100
  • Annual Revenue: $500M-1 Billion
  • www.visustx.com
  • 2 Nickerson Street Suite 101
    Seattle, WA USA 98109
  • Phone: 800.281.4536

Executives

Name Title Contact Details

Funding

Visus Therapeutics raised $36M on 03/09/2021

Similar Companies

ISTA Pharmaceuticals

ISTA Pharmaceuticals, Inc. is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nulixir

Nulixir is a B2B nanobiotechnology company that develops, manufactures, and licenses intellectual property for smart nanocarriers, called nanovesicles, which optimize the performance of functional ingredients in food & beverage products.

TrueScripts Management Services

United Pharma

United Pharma is a Fullerton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DynPort Vaccine Company

DynPort Vaccine Company LLC (DVC) provides an integrated approach for the advanced development of specific vaccines and other products to protect our nation against the threat of bio-warfare agents. This development effort includes process refinement,